Its prognostic power was independent of other predictors, stratified lymph node+ HER2+ BC into low- and high-risk subgroups, and was specific for HER2+:ERα− patients (hazard ratio (HR)=5.57; P=0.002)). Here, ERBB2 is linked to breast cancer.